
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **November 5, 2013**

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

(Commission File Number)

22-0760120

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

(Address of Principal Executive Offices)

07417-1880

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 5, 2013, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2013. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- **Revenues.** We present international and total revenue growth rates (for the total company and each of its segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.
- **Earnings Per Share from Continuing Operations.** We present diluted earnings per share from continuing operations (“EPS”) for the fourth quarter of fiscal year 2013 after eliminating (i) a charge relating to the verdict in BD’s litigation with Retractable Technologies, Inc., and (ii) a charge relating to non-cash pension settlements. We also present EPS for the 2013 fiscal year after eliminating the foregoing fourth quarter charges and the third quarter charge relating to an antitrust class action settlement. We also present EPS for the fourth quarter of fiscal year 2012 and for the full 2012 fiscal year after eliminating a charge resulting from primarily non-cash pension settlements. In each instance, we adjust for these charges because they are not considered by management to be part of our ordinary operations and adjusting for these charges allows investors to better understand our underlying results.

We also show EPS for the fourth quarter and 2013 fiscal year, as adjusted above, after further eliminating the impact of the medical device excise tax that went into effect in January 2013 under the U.S. healthcare reform law. We believe adjusting for the impact of the medical device excise tax facilitates comparisons to prior periods as this tax was not in effect for those prior periods. We also present EPS growth rates for the fourth quarter and 2013 fiscal year after further adjusting for the impact of foreign currency translation during these periods. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.

We also present estimated EPS guidance for fiscal year 2014 after adjusting for the anticipated impact of foreign currency translation and the one quarter of incremental impact from the medical device excise tax that BD will have in fiscal year 2014 compared to fiscal year 2013. Management believes eliminating the effects of foreign currency translation and the incremental impact of the excise tax allows investors to better understand our guidance in relation to fiscal year 2013 and the anticipated underlying performance of BD.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods and to the performance of peer companies. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated November 5, 2013, which is furnished pursuant to Item 2.02

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Gary DeFazio
Gary DeFazio
Vice President and Corporate Secretary

Date: November 5, 2013

99.1 Press release dated November 5, 2013, which is furnished pursuant to Item 2.02



Contact:

Monique N. Dolecki, Investor Relations – 201-847-5453
Alyssa J. Zeff, Corporate Communications – 201-847-4358

**BD ANNOUNCES RESULTS FOR 2013 FOURTH FISCAL QUARTER AND FULL YEAR;
PROVIDES FISCAL 2014 GUIDANCE**

- Reports adjusted diluted earnings per share from continuing operations of \$5.81 for the full fiscal year, in-line with the Company's expectations. Reported diluted earnings per share from continuing operations were \$4.67.
- Expects full fiscal year 2014 diluted earnings per share from continuing operations to be between \$6.16 and \$6.22, an increase of 6.0 to 7.0 percent, on an adjusted basis. On a currency-neutral basis the Company expects adjusted earnings per share to grow between 8.5 to 9.5 percent, or 9.0 to 10.0 percent excluding the incremental impact of the medical device tax.
- Announces planned stock repurchases of about \$450 million in fiscal year 2014.

Franklin Lakes, NJ (November 5, 2013)– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$2.1 billion for the fourth fiscal quarter ended September 30, 2013, representing an increase of 6.8 percent from the prior-year period, or 7.2 percent on a foreign currency-neutral basis. Revenue growth in the quarter was aided, in part, by some one-time items. For the full fiscal year ended September 30, 2013, BD reported revenues of \$8.1 billion, representing an increase of 4.5 percent over the prior-year period or 5.4 percent on a foreign currency-neutral basis.

“We are proud of our accomplishments during fiscal year 2013,” said Vincent A. Forlenza, Chairman, CEO and President. “Our strategy of investing and innovating for growth is succeeding. We exceeded our financial and operating goals this year while continuing to deliver on our long-term commitments. We look forward to fiscal year 2014 with confidence.”

Fourth Quarter Fiscal 2013 Discussion

Diluted earnings per share from continuing operations for the fourth quarter were \$0.46, compared with \$1.35 in the prior-year period. Current quarter results included a pre-tax charge from the RTI verdict of \$341 million, or \$1.06 diluted earnings per share from continuing operations, and a charge from non-cash pension settlements of \$6 million, or \$0.02 diluted earnings per share from continuing operations. Results in the prior-year's quarter included a charge of \$20 million, or \$0.07 diluted earnings per share from continuing operations, resulting from primarily non-cash pension settlements. Excluding these items, adjusted diluted earnings per share from continuing operations were \$1.54 compared with \$1.42 in the prior-year period. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were \$1.58. This represents growth of 11.3 percent, or 12.0 percent on an adjusted foreign currency-neutral basis.

For the full fiscal year ended September 30, 2013, diluted earnings per share from continuing operations were \$4.67, compared with \$5.30 in the prior-year period. Adjusted diluted earnings per share from continuing operations were \$5.81 compared with \$5.37 in the prior-year period. This excludes the aforementioned fourth quarter charges as well as the third quarter fiscal year 2013 charge related to the antitrust class action settlement of \$22 million, or \$0.07 diluted earnings per share from continuing operations. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax were \$5.95. This represents growth of 10.8 percent, or 11.9 percent on an adjusted foreign currency-neutral basis.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$1.1 billion, representing an increase of 6.8 percent compared with the prior-year period, or 6.7 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Medical Surgical Systems and Pharmaceutical Systems units. For the twelve-month period ended September 30, 2013, BD Medical revenues increased 5.3 percent, or 6.0 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$680 million, representing an increase of 5.4 percent compared with the prior-year period, or 6.3 percent on a foreign currency-neutral basis. The segment's growth was driven by solid sales of Preanalytical Systems' safety-engineered products, and strong sales within the Diagnostic Systems unit partially driven by Kiestra Lab Automation installations. For the twelve-month period ended September 30, 2013, BD Diagnostics revenues increased 4.3 percent, or 5.2 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$300 million, representing an increase of 10.0 percent compared with the prior-year period, or an increase of 11.6 percent on a foreign currency-neutral basis. The segment's growth was driven by solid instrument placements in Cell Analysis, the reversal of an unfavorable timing of orders in the third quarter in Advanced Bioprocessing, and government funding in Japan. For the twelve-month period ended September 30, 2013, BD Biosciences revenues increased 2.0 percent, or an increase of 3.6 percent on a foreign currency-neutral basis.

Geographic Results

Fourth quarter revenues in the U.S. of \$851 million represent an increase of 3.4 percent over the prior-year period. Growth in the U.S. was driven by the Pharmaceutical Systems unit, which benefitted from the acquisition of Safety Syringes and strong orders, partially offset by softness in Women's Health and Cancer. Revenues outside of the U.S. were \$1.2 billion, representing an increase of 9.3 percent compared with the prior-year period, or 10.1 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products.

For the twelve-month period ended September 30, 2013, revenues in the U.S. were \$3.4 billion, representing an increase of 2.0 percent compared with the prior-year period. Revenues outside of the U.S. were \$4.7 billion, representing an increase of 6.3 percent compared with the prior-year period, or 8.0 percent on a foreign currency-neutral basis.

Fiscal 2014 Outlook for Full Year

The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.0 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between \$6.16 and \$6.22, which represents growth of 6.0 to 7.0 percent over 2013 adjusted diluted earnings per share of \$5.81. On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 8.5 to 9.5 percent, or 9.0 to 10.0 percent excluding the incremental impact of the medical device tax. The Company plans to repurchase, subject to market conditions, about \$450 million of its common stock in 2014.

Conference Call Information

A conference call regarding BD's fourth quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, November 5th, 2013. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, November 12, 2013, confirmation number 69586788.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare

institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures, including "sequestration", which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; the adverse impact of cyber-attacks on our information systems; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share data)

	Three Months Ended September 30,		
	2013	2012	% Change
REVENUES	\$ 2,101	\$ 1,967	6.8
Cost of products sold	1,014	966	5.0
Selling and administrative	877	484	81.2
Research and development	133	128	3.8
TOTAL OPERATING COSTS AND EXPENSES	2,024	1,578	28.3
OPERATING INCOME	76	389	(80.4)
Interest income	14	12	16.9
Interest expense	(34)	(35)	(3.3)
Other income (expense), net	3	(4)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	60	362	(83.5)
Income tax (benefit) provision	(31)	88	NM
INCOME FROM CONTINUING OPERATIONS	91	274	(66.8)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$1 AND \$9, RESPECTIVELY	—	15	NM
NET INCOME	\$ 91	\$ 289	(68.7)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.47	\$ 1.38	(65.9)
Income from discontinued operations	\$ —	\$ 0.07	NM
Net income	\$ 0.46	\$ 1.45	(68.3)
Diluted:			
Income from continuing operations	\$ 0.46	\$ 1.35	(65.9)
Income from discontinued operations	\$ —	\$ 0.07	NM
Net income	\$ 0.46	\$ 1.43	(67.8)
AVERAGE SHARES OUTSTANDING (in thousands)			
Basic	194,697	199,072	
Diluted	198,628	202,439	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in millions, except share and per share data)

	Twelve Months Ended September 30,		
	2013	2012	% Change
REVENUES	\$ 8,054	\$ 7,708	4.5
Cost of products sold	3,883	3,755	3.4
Selling and administrative	2,422	1,923	25.9
Research and development	494	472	4.8
TOTAL OPERATING COSTS AND EXPENSES	6,800	6,150	10.6
OPERATING INCOME	1,254	1,558	(19.5)
Interest income	40	50	(20.6)
Interest expense	(138)	(135)	2.8
Other income (expense), net	9	(1)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,165	1,472	(20.9)
Income tax provision	236	363	(35.1)
INCOME FROM CONTINUING OPERATIONS	929	1,110	(16.2)
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$222 AND \$31, RESPECTIVELY	364	60	NM
NET INCOME	\$ 1,293	\$ 1,170	10.5
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 4.76	\$ 5.40	(11.9)
Income from discontinued operations	\$ 1.86	\$ 0.29	NM
Net income	\$ 6.63	\$ 5.69	16.5
Diluted:			
Income from continuing operations	\$ 4.67	\$ 5.30	(11.9)
Income from discontinued operations	\$ 1.83	\$ 0.29	NM
Net income	\$ 6.49	\$ 5.59	16.1
AVERAGE SHARES OUTSTANDING (in thousands)			
Basic	195,157	205,460	
Diluted	199,193	209,181	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in millions)

	Three Months Ended September 30,		
	2013	2012	% Change
BD MEDICAL			
United States	\$ 440	\$ 422	4.3
International	680	627	8.5
TOTAL	\$ 1,120	\$ 1,049	6.8
BD DIAGNOSTICS			
United States	\$ 319	\$ 314	1.6
International	361	331	9.0
TOTAL	\$ 680	\$ 645	5.4
BD BIOSCIENCES			
United States	\$ 92	\$ 88	5.0
International	208	185	12.3
TOTAL	\$ 300	\$ 273	10.0
TOTAL REVENUES			
United States	\$ 851	\$ 824	3.4
International	1,249	1,143	9.3
TOTAL	\$ 2,101	\$ 1,967	6.8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in millions)

	Twelve Months Ended September 30,		
	2013	2012	% Change
BD MEDICAL			
United States	\$ 1,727	\$ 1,685	2.5
International	<u>2,579</u>	<u>2,406</u>	<u>7.2</u>
TOTAL	<u>\$ 4,306</u>	<u>\$ 4,091</u>	<u>5.3</u>
BD DIAGNOSTICS			
United States	\$ 1,272	\$ 1,259	1.0
International	<u>1,374</u>	<u>1,279</u>	<u>7.4</u>
TOTAL	<u>\$ 2,646</u>	<u>\$ 2,538</u>	<u>4.3</u>
BD BIOSCIENCES			
United States	\$ 354	\$ 343	3.1
International	<u>748</u>	<u>736</u>	<u>1.6</u>
TOTAL	<u>\$ 1,102</u>	<u>\$ 1,080</u>	<u>2.0</u>
TOTAL REVENUES			
United States	\$ 3,353	\$ 3,288	2.0
International	<u>4,701</u>	<u>4,421</u>	<u>6.3</u>
TOTAL	<u>\$ 8,054</u>	<u>\$ 7,708</u>	<u>4.5</u>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in millions)

	United States		
	2013	2012	% Change
<u>BD MEDICAL</u>			
Medical Surgical Systems	\$252	\$251	0.6
Diabetes Care	113	113	0.3
Pharmaceutical Systems	75	59	27.6
TOTAL	\$440	\$422	4.3
<u>BD DIAGNOSTICS</u>			
Preanalytical Systems	\$170	\$165	3.2
Diagnostic Systems	149	149	(0.1)
TOTAL	\$319	\$314	1.6
<u>BD BIOSCIENCES</u>	\$ 92	\$ 88	5.0
TOTAL UNITED STATES	\$851	\$824	3.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in millions)

	International				
	2013	2012	Reported	% Change	
				FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 308	\$ 282	9.4	11.1	(1.7)
Diabetes Care	131	120	8.7	11.2	(2.5)
Pharmaceutical Systems	241	225	7.3	3.3	4.0
TOTAL	\$ 680	\$ 627	8.5	8.3	0.2
BD DIAGNOSTICS					
Preanalytical Systems	\$ 172	\$ 163	6.0	6.8	(0.8)
Diagnostic Systems	189	168	12.0	14.6	(2.6)
TOTAL	\$ 361	\$ 331	9.0	10.8	(1.8)
BD BIOSCIENCES	\$ 208	\$ 185	12.3	14.7	(2.4)
TOTAL INTERNATIONAL	\$1,249	\$1,143	9.3	10.1	(0.8)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in millions)

			Total		
	2013	2012	Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 560	\$ 532	5.2	6.2	(1.0)
Diabetes Care	244	233	4.7	5.9	(1.2)
Pharmaceutical Systems	316	283	11.5	8.3	3.2
TOTAL	\$1,120	\$1,049	6.8	6.7	0.1
BD DIAGNOSTICS					
Preanalytical Systems	\$ 342	\$ 328	4.6	5.0	(0.4)
Diagnostic Systems	338	318	6.3	7.7	(1.4)
TOTAL	\$ 680	\$ 645	5.4	6.3	(0.9)
BD BIOSCIENCES	\$ 300	\$ 273	10.0	11.6	(1.6)
TOTAL REVENUES	\$2,101	\$1,967	6.8	7.2	(0.4)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in millions)

	United States		
	2013	2012	% Change
<u>BD MEDICAL</u>			
Medical Surgical Systems	\$ 983	\$ 978	0.5
Diabetes Care	450	434	3.5
Pharmaceutical Systems	294	273	7.9
TOTAL	\$1,727	\$1,685	2.5
<u>BD DIAGNOSTICS</u>			
Preanalytical Systems	\$ 666	\$ 656	1.5
Diagnostic Systems	606	603	0.5
TOTAL	\$1,272	\$1,259	1.0
BD BIOSCIENCES	\$ 354	\$ 343	3.1
TOTAL UNITED STATES	\$3,353	\$3,288	2.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in millions)

	International				
	2013	2012	Reported	% Change FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$1,213	\$1,127	7.6	9.3	(1.7)
Diabetes Care	519	477	8.9	11.7	(2.8)
Pharmaceutical Systems	847	801	5.8	5.6	0.2
TOTAL	\$2,579	\$2,406	7.2	8.5	(1.3)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 686	\$ 645	6.4	7.9	(1.5)
Diagnostic Systems	688	634	8.5	11.0	(2.5)
TOTAL	\$1,374	\$1,279	7.4	9.4	(2.0)
BD BIOSCIENCES	\$ 748	\$ 736	1.6	3.8	(2.2)
TOTAL INTERNATIONAL	\$4,701	\$4,421	6.3	8.0	(1.7)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in millions)

	Total				
	2013	2012	Reported	% Change	
				FXN	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$2,196	\$2,105	4.3	5.2	(0.9)
Diabetes Care	969	911	6.3	7.8	(1.5)
Pharmaceutical Systems	<u>1,142</u>	<u>1,074</u>	<u>6.3</u>	<u>6.2</u>	<u>0.1</u>
TOTAL	<u>\$4,306</u>	<u>\$4,091</u>	<u>5.3</u>	<u>6.0</u>	<u>(0.7)</u>
BD DIAGNOSTICS					
Preanalytical Systems	\$1,352	\$1,301	3.9	4.7	(0.8)
Diagnostic Systems	<u>1,294</u>	<u>1,237</u>	<u>4.6</u>	<u>5.9</u>	<u>(1.3)</u>
TOTAL	<u>\$2,646</u>	<u>\$2,538</u>	<u>4.3</u>	<u>5.2</u>	<u>(0.9)</u>
BD BIOSCIENCES	<u>\$1,102</u>	<u>\$1,080</u>	<u>2.0</u>	<u>3.6</u>	<u>(1.6)</u>
TOTAL REVENUES	<u>\$8,054</u>	<u>\$7,708</u>	<u>4.5</u>	<u>5.4</u>	<u>(0.9)</u>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in millions)

	Three Months Ended September 30,				
	2013	2012	Reported	% Change	
			FXN	FX Impact	
TOTAL SAFETY REVENUES					
United States	\$303	\$291	4.2	4.2	—
International	233	216	7.9	9.5	(1.6)
TOTAL	\$536	\$507	5.7	6.4	(0.7)
BY SEGMENT					
BD Medical	\$269	\$251	7.3	8.2	(0.9)
BD Diagnostics	267	256	4.2	4.7	(0.5)
TOTAL	\$536	\$507	5.7	6.4	(0.7)
	Twelve Months Ended September 30,				
	2013	2012	Reported	% Change	
			FXN	FX Impact	
TOTAL SAFETY REVENUES					
United States	\$1,182	\$1,149	2.9	2.9	—
International	917	834	10.0	11.9	(1.9)
TOTAL	\$2,099	\$1,983	5.9	6.6	(0.7)
BY SEGMENT					
BD Medical	\$1,045	\$ 966	8.1	9.0	(0.9)
BD Diagnostics	1,054	1,017	3.7	4.4	(0.7)
TOTAL	\$2,099	\$1,983	5.9	6.6	(0.7)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2013 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures
(Unaudited)

	Three Months Ended September 30,						
	<u>2013</u>	<u>2012</u>	<u>Growth</u>	<u>Foreign Currency Translation</u>	<u>Foreign Currency Neutral Change</u>	<u>Growth %</u>	<u>Foreign Currency Neutral Growth %</u>
Reported Diluted Earnings per Share from Continuing Operations	<u>\$0.46</u>	<u>\$1.35</u>	<u>\$(0.89)</u>	<u>\$ (0.01)</u>	<u>\$ (0.88)</u>	<u>(65.9%)</u>	<u>(65.2%)</u>
Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI (\$341 million or \$211 million after-tax)	1.06	0.00					
Non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans. (\$6 million or \$4 million after-tax and \$20 million or \$13 million after-tax, respectively)	<u>0.02</u>	<u>0.07</u>					
Adjusted Diluted Earnings per Share from Continuing Operations	<u>\$1.54</u>	<u>\$1.42</u>	<u>\$ 0.12</u>	<u>\$ (0.01)</u>	<u>\$ 0.13</u>	<u>8.5%</u>	<u>9.2%</u>
Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act (\$13 million or \$8 million after-tax)	<u>0.04</u>	<u>0.00</u>					
Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax	<u>\$1.58</u>	<u>\$1.42</u>	<u>\$ 0.16</u>	<u>\$ (0.01)</u>	<u>\$ 0.17</u>	<u>11.3%</u>	<u>12.0%</u>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2013 Year-to-Date Reconciliation of Non-GAAP Financial Measures
(Unaudited)

	Twelve Months Ended September 30,						
	<u>2013</u>	<u>2012</u>	<u>Growth</u>	<u>Foreign Currency Translation</u>	<u>Foreign Currency Neutral Change</u>	<u>Growth %</u>	<u>Foreign Currency Neutral Growth %</u>
Reported Diluted Earnings per Share from Continuing Operations	\$4.67	\$5.30	\$(0.63)	\$ (0.06)	\$ (0.57)	(11.9%)	(10.8%)
Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases (\$22 million or \$14 million after-tax)	0.07	0.00					
Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI (\$341 million or \$211 million after-tax)	1.06	0.00					
Non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans. (\$6 million or \$4 million after-tax and \$20 million or \$13 million after-tax, respectively)	0.02	0.06					
Adjusted Diluted Earnings per Share from Continuing Operations	\$5.81	\$5.37	\$ 0.44	\$ (0.06)	\$ 0.50	8.2%	9.3%
Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act (\$40 million or \$26 million after-tax)	0.13	0.00					
Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax	\$5.95	\$5.37	\$ 0.58	\$ (0.06)	\$ 0.64	10.8%	11.9%

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2014 Outlook Reconciliation

	Reported Basis	FX Impact	FXN Basis
Revenues - Full Year 2014 estimated growth	4.0% - 5.0%	0.0%	4.0% - 5.0%
	Full Year 2014 (estimated)	Full Year 2013	% Increase
Reported Fully Diluted Earnings per Share from Continuing Operations	\$ 6.16 - 6.22	\$ 4.67	NM
Pending Litigation Settlement ⁽¹⁾		0.07	
Verdict Charge ⁽²⁾		1.06	
Pension Settlement Charge ⁽³⁾		<u>0.02</u>	
Adjusted Fully Diluted Earnings per Share from Continuing Operations	<u>\$ 6.16 - 6.22</u>	<u>\$ 5.81</u>	6.0% - 7.0%
FX Impact			<u>(2.5%)</u>
Adjusted FXN Growth			8.5% - 9.5%
Medical Device Excise Tax Impact ⁽⁴⁾			<u>(0.5%)</u>
Adjusted FXN Growth (excluding the medical device excise tax)			9.0% - 10.0%

⁽¹⁾ Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.

⁽²⁾ Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.

⁽³⁾ Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.

⁽⁴⁾ Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).

NM - Not Meaningful

FXN = Foreign Currency Neutral